Maze Therapeutics Inc. Insider Trading

MAZE

Last 12 months

Insiders sold $25M and bought nothing on the open market.

91% of the selling was scheduled in advance under 10b5-1 plans. Director Catherine A. Sohn sold $1.15M on Jan 7, 100% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$25M

0 buys · 45 sales

Under a 10b5-1 plan

91%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

None

in the last two years

Get an email when MAZE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 4 parts	34,501	$30.25 average	$1.04M	15%	Form 4
Oct 29	Atul Dandekar Csbo	Sold10b5-1 plan	7,500	$32.07	241K	19%	Form 4
Oct 1	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 2 parts	34,501	$27.02 average	932K	13%	Form 4
Oct 1	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan	16,141	$26.93	435K	100%	Form 4
Sep 29	Atul Dandekar Csbo	Sold10b5-1 plan	7,500	$27.06	203K	19%	Form 4
Sep 4	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan	9,705	$26.22	254K	100%	Form 4
Sep 2 – 3	Harold Bernstein President, R&D & CMO	SoldNo plan 4 parts	10,295	$26.24 average	270K	51%	Form 4
Sep 2 – 3	Atul Dandekar Csbo	SoldNo plan 4 parts	6,434	$26.24 average	169K	17%	Form 4
Sep 2 – 3	Phillips Courtney GC and Corp. Secretary	SoldNo plan 4 parts	3,993	$26.24 average	105K	36%	Form 4
Sep 2 – 3	Jason V Coloma Chief Executive Officer	SoldNo plan 4 parts	22,638	$26.24 average	594K	7.8%	Form 4
Sep 1	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan	16,141	$26.36	425K	45%	Form 4
Sep 1	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 2 parts	34,501	$26.29 average	907K	11%	Form 4
Aug 28	Atul Dandekar Csbo	Sold10b5-1 plan	7,500	$27.58	207K	22%	Form 4
Aug 13	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan	16,142	$27.61	446K	100%	Form 4
Aug 3	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 4 parts	34,501	$26.73 average	922K	11%	Form 4
Jul 29	Atul Dandekar Csbo	Sold10b5-1 plan 2 parts	7,500	$27.34 average	205K	22%	Form 4
Jul 1	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan 2 parts	14,609	$29.91 average	437K	100%	Form 4
Jul 1	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 3 parts	34,501	$29.97 average	$1.03M	10%	Form 4
Jun 29	Atul Dandekar Csbo	Sold10b5-1 plan	7,500	$28.02	210K	22%	Form 4
Jun 22 – 23	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 3 parts	27,858	$26.04 average	726K	7.5%	Form 4
Jun 1	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan 2 parts	14,853	$25.66 average	381K	100%	Form 4
Jun 1	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 2 parts	6,643	$26.20 average	174K	1.8%	Form 4
May 29	Atul Dandekar Csbo	Sold10b5-1 plan	7,500	$26.34	198K	23%	Form 4
May 22 – 26	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 3 parts	32,564	$26.02 average	847K	7.9%	Form 4
May 15	Jason V Coloma Chief Executive Officer	Sold10b5-1 plan 2 parts	1,938	$26.00 average	50K	0.5%	Form 4
May 14	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan	15,000	$26.22	393K	100%	Form 4
Apr 29	Atul Dandekar Csbo	Sold10b5-1 plan	7,500	$25.37	190K	42%	Form 4
Apr 1	Amy Bachrodt SVP, Finance	Sold10b5-1 plan 2 parts	2,500	$29.44 average	74K	16%	Form 4
Apr 1	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan 3 parts	15,000	$29.46 average	442K	100%	Form 4
Mar 30	Atul Dandekar Csbo	Sold10b5-1 plan 2 parts	7,500	$29.34 average	220K	42%	Form 4
Mar 20	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan 3 parts	15,000	$49.10 average	736K	100%	Form 4
Mar 10	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan 2 parts	30,000	$50.46 average	$1.51M	100%	Form 4
Mar 2	Amy Bachrodt SVP, Finance	Sold10b5-1 plan 2 parts	5,000	$45.20 average	226K	28%	Form 4
Feb 27	Atul Dandekar Csbo	Sold10b5-1 plan 2 parts	7,500	$45.43 average	341K	42%	Form 4
Feb 2	Amy Bachrodt SVP, Finance	Sold10b5-1 plan 3 parts	5,000	$46.04 average	230K	28%	Form 4
Feb 2	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan 4 parts	15,000	$46.02 average	690K	100%	Form 4
Jan 29	Atul Dandekar Csbo	Sold10b5-1 plan 3 parts	7,500	$44.26 average	332K	42%	Form 4
Jan 22	Amy Bachrodt SVP, Finance	Sold10b5-1 plan	5,000	$45.52	228K	28%	Form 4
Jan 7	Harold Bernstein President, R&D & CMO	Sold10b5-1 plan	25,156	$40.20	$1.01M	100%	Form 4
Jan 6 – 7	Catherine A. Sohn Director	SoldNo plan 2 parts	29,413	$39.07 average	$1.15M	100%	Form 4

Nov 210b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 34,501 at avg $30.25
$1.04M
15% of stake
Oct 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at $32.07
241K
19% of stake
Oct 110b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 34,501 at avg $27.02
932K
13% of stake
Oct 110b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 16,141 at $26.93
435K
100% of stake
Sep 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at $27.06
203K
19% of stake
Sep 410b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 9,705 at $26.22
254K
100% of stake
Sep 2 – 3No plan
Harold Bernstein
President, R&D & CMO · sold 10,295 at avg $26.24
270K
51% of stake
Sep 2 – 3No plan
Atul Dandekar
Csbo · sold 6,434 at avg $26.24
169K
17% of stake
Sep 2 – 3No plan
Phillips Courtney
GC and Corp. Secretary · sold 3,993 at avg $26.24
105K
36% of stake
Sep 2 – 3No plan
Jason V Coloma
Chief Executive Officer · sold 22,638 at avg $26.24
594K
7.8% of stake
Sep 110b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 16,141 at $26.36
425K
45% of stake
Sep 110b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 34,501 at avg $26.29
907K
11% of stake
Aug 2810b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at $27.58
207K
22% of stake
Aug 1310b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 16,142 at $27.61
446K
100% of stake
Aug 310b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 34,501 at avg $26.73
922K
11% of stake
Jul 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at avg $27.34
205K
22% of stake
Jul 110b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 14,609 at avg $29.91
437K
100% of stake
Jul 110b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 34,501 at avg $29.97
$1.03M
10% of stake
Jun 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at $28.02
210K
22% of stake
Jun 22 – 2310b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 27,858 at avg $26.04
726K
7.5% of stake
Jun 110b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 14,853 at avg $25.66
381K
100% of stake
Jun 110b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 6,643 at avg $26.20
174K
1.8% of stake
May 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at $26.34
198K
23% of stake
May 22 – 2610b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 32,564 at avg $26.02
847K
7.9% of stake
May 1510b5-1 plan
Jason V Coloma
Chief Executive Officer · sold 1,938 at avg $26.00
50K
0.5% of stake
May 1410b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 15,000 at $26.22
393K
100% of stake
Apr 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at $25.37
190K
42% of stake
Apr 110b5-1 plan
Amy Bachrodt
SVP, Finance · sold 2,500 at avg $29.44
74K
16% of stake
Apr 110b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 15,000 at avg $29.46
442K
100% of stake
Mar 3010b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at avg $29.34
220K
42% of stake
Mar 2010b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 15,000 at avg $49.10
736K
100% of stake
Mar 1010b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 30,000 at avg $50.46
$1.51M
100% of stake
Mar 210b5-1 plan
Amy Bachrodt
SVP, Finance · sold 5,000 at avg $45.20
226K
28% of stake
Feb 2710b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at avg $45.43
341K
42% of stake
Feb 210b5-1 plan
Amy Bachrodt
SVP, Finance · sold 5,000 at avg $46.04
230K
28% of stake
Feb 210b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 15,000 at avg $46.02
690K
100% of stake
Jan 2910b5-1 plan
Atul Dandekar
Csbo · sold 7,500 at avg $44.26
332K
42% of stake
Jan 2210b5-1 plan
Amy Bachrodt
SVP, Finance · sold 5,000 at $45.52
228K
28% of stake
Jan 710b5-1 plan
Harold Bernstein
President, R&D & CMO · sold 25,156 at $40.20
$1.01M
100% of stake
Jan 6 – 7No plan
Catherine A. Sohn
Director · sold 29,413 at avg $39.07
$1.15M
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MAZE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with MAZE

CompareIntrinsic value

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

PROKProKidney Corp

$1.12+4.67%10

MGXMetagenomi, Inc.

$0.79+3.95%10

PALIPalisade Bio Inc.

$1.25+1.63%20

ENTXEntera Bio Ltd.

$3.11+1.97%20

ELOXEloxx Pharmaceuticals, Inc.

$12.74-1.39%20

CMPXCompass Therapeutics Inc.

$0.76+1.33%10

SABSSab Biotherapeutics Inc.

$3.18+1.92%19

Held by ETFs

MAZE is in 35 US ETFs. The largest of them, with MAZE's weight in each:

Spot a number that looks wrong? Check it in MAZE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MAZE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.